Panobinostat for the treatment of multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Panobinostat for the treatment of multiple myeloma

Published:2012-03-12 Issue:5 Volume:21 Page:733-747
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Neri Paola¹²,Bahlis Nizar J¹²,Lonial Sagar³

Affiliation:

1. Division of Hematology and Bone Marrow Transplant, University of Calgary, AB, Canada

2. Southern Alberta, Cancer Research Institute (SACRI), Calgary, AB, Canada

3. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/13543784.2012.668883

Reference101 articles.

1. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

2. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

3. The Epigenomics of Cancer

4. Histone deacetylases, transcriptional control, and cancer

5. Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implementation of green analytical principles to develop and validate the HPLC method for the separation and identification of degradation products of Panobinostat, and its characterization by using LC-QTOF-MS/MS and its in-silico toxicity prediction using ADMET software;Green Analytical Chemistry;2024-03

2. The Impact of Panobinostat on Cell Death in Combination with S63845 in Multiple Myeloma Cells;Indian Journal of Hematology and Blood Transfusion;2023-01-02

3. Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers;Fundamental & Clinical Pharmacology;2022-10-08

4. The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer;Cancer Biology & Medicine;2022-07-15

5. Discovery of 2-Phenylquinoline-4-Carboxylic Acid Derivatives as Novel Histone Deacetylase Inhibitors;Frontiers in Chemistry;2022-07-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3